Grant Pickering, Vaxcyte CEO
Vaxcyte's data lead to $600M haul, while Taysha looks to raise cash after Astellas deal
It’s only been a few days since Vaxcyte gave the biotech world a peek at data for its 24-valent pneumococcal vaccine, but the company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
